133 related articles for article (PubMed ID: 30739826)
1. Synthesis and structure-activity relationship studies of parthenolide derivatives as potential anti-triple negative breast cancer agents.
Ge W; Hao X; Han F; Liu Z; Wang T; Wang M; Chen N; Ding Y; Chen Y; Zhang Q
Eur J Med Chem; 2019 Mar; 166():445-469. PubMed ID: 30739826
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and anti-acute myeloid leukemia activity of C-14 modified parthenolide derivatives.
Yang Z; Kuang B; Kang N; Ding Y; Ge W; Lian L; Gao Y; Wei Y; Chen Y; Zhang Q
Eur J Med Chem; 2017 Feb; 127():296-304. PubMed ID: 28068601
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of melampomagnolide B derivatives as potential anti-Triple Negative Breast Cancer agents.
Chen T; Chen X; Liu L; Zhang Q; Ding Y
Eur J Med Chem; 2024 Jan; 264():116024. PubMed ID: 38104376
[TBL] [Abstract][Full Text] [Related]
4. Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells.
Ding Y; Chen X; Liu C; Ge W; Wang Q; Hao X; Wang M; Chen Y; Zhang Q
J Hematol Oncol; 2021 Jan; 14(1):19. PubMed ID: 33472669
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, Crystal Study, and Anti-Proliferative Activity of Some 2-Benzimidazolylthioacetophenones towards Triple-Negative Breast Cancer MDA-MB-468 Cells as Apoptosis-Inducing Agents.
Abdel-Aziz HA; Eldehna WM; Ghabbour H; Al-Ansary GH; Assaf AM; Al-Dhfyan A
Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27483243
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of parthenolide and 5-fluorouracil conjugates as potential anticancer agents against drug resistant hepatocellular carcinoma.
Ding Y; Li S; Ge W; Liu Z; Zhang X; Wang M; Chen T; Chen Y; Zhang Q
Eur J Med Chem; 2019 Dec; 183():111706. PubMed ID: 31553932
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of parthenolide-SAHA hybrids for intervention of drug-resistant acute myeloid leukemia.
Ge W; Liu Z; Sun Y; Wang T; Guo H; Chen X; Li S; Wang M; Chen Y; Ding Y; Zhang Q
Bioorg Chem; 2019 Jun; 87():699-713. PubMed ID: 30953889
[TBL] [Abstract][Full Text] [Related]
8. One-pot three-component synthesis of novel spirooxindoles with potential cytotoxic activity against triple-negative breast cancer MDA-MB-231 cells.
Eldehna WM; El-Naggar DH; Hamed AR; Ibrahim HS; Ghabbour HA; Abdel-Aziz HA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):309-318. PubMed ID: 29281924
[TBL] [Abstract][Full Text] [Related]
9. Novel sesquiterpene lactone analogues as potent anti-breast cancer agents.
Nakagawa-Goto K; Chen JY; Cheng YT; Lee WL; Takeya M; Saito Y; Lee KH; Shyur LF
Mol Oncol; 2016 Jun; 10(6):921-37. PubMed ID: 27055598
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of dual-action parthenolide prodrugs as potent anticancer agents.
Taleghani A; Nasseri MA; Iranshahi M
Bioorg Chem; 2017 Apr; 71():128-134. PubMed ID: 28215600
[TBL] [Abstract][Full Text] [Related]
11. Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
Chen L; Long C; Nguyen J; Kumar D; Lee J
Bioorg Med Chem Lett; 2018 Feb; 28(3):420-424. PubMed ID: 29287960
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Anti-TNBC Agents Targeting PTP1B: Total Synthesis, Structure-Activity Relationship,
Hu C; Li G; Mu Y; Wu W; Cao B; Wang Z; Yu H; Guan P; Han L; Li L; Huang X
J Med Chem; 2021 May; 64(9):6008-6020. PubMed ID: 33860662
[TBL] [Abstract][Full Text] [Related]
13. From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
Zhang CH; Chen K; Jiao Y; Li LL; Li YP; Zhang RJ; Zheng MW; Zhong L; Huang SZ; Song CL; Lin WT; Yang J; Xiang R; Peng B; Han JH; Lu GW; Wei YQ; Yang SY
J Med Chem; 2016 Nov; 59(21):9788-9805. PubMed ID: 27739679
[TBL] [Abstract][Full Text] [Related]
14. Copper(I) oxide nanoparticles catalyzed click chemistry based synthesis of melampomagnolide B-triazole conjugates and their anti-cancer activities.
Ding Y; Guo H; Ge W; Chen X; Li S; Wang M; Chen Y; Zhang Q
Eur J Med Chem; 2018 Aug; 156():216-229. PubMed ID: 30006167
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and structure-activity relationship study of a potent MHO7 analogue as potential anti-triple negative breast cancer agent.
Liang JJ; Yu WL; Yang L; Qin KM; Yin YP; Li D; Ni YH; Yan JJ; Zhong YX; Deng ZX; Hong K
Eur J Med Chem; 2022 Jun; 236():114313. PubMed ID: 35390712
[TBL] [Abstract][Full Text] [Related]
16. Novel merosesquiterpene exerts a potent antitumor activity against breast cancer cells in vitro and in vivo.
Carrasco E; Álvarez PJ; Melguizo C; Prados J; Álvarez-Manzaneda E; Chahboun R; Messouri I; Vázquez-Vázquez MI; Aránega A; Rodríguez-Serrano F
Eur J Med Chem; 2014 May; 79():1-12. PubMed ID: 24704691
[TBL] [Abstract][Full Text] [Related]
17. Selenocystine-induced cell apoptosis and S-phase arrest inhibit human triple-negative breast cancer cell proliferation.
Long M; Wu J; Hao J; Liu W; Tang Y; Li X; Su H; Qiu W
In Vitro Cell Dev Biol Anim; 2015 Nov; 51(10):1077-84. PubMed ID: 26194802
[TBL] [Abstract][Full Text] [Related]
18. Novel racemosin B derivatives as new therapeutic agents for aggressive breast cancer.
Xiao X; Xu M; Yang C; Yao Y; Liang LN; Ed Chung P; Long Q; Zacksenhaus E; He Z; Liu S; Ben-David Y
Bioorg Med Chem; 2018 Dec; 26(23-24):6096-6104. PubMed ID: 30471828
[TBL] [Abstract][Full Text] [Related]
19. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
[TBL] [Abstract][Full Text] [Related]
20. New bis(hydroxymethyl) alkanoate curcuminoid derivatives exhibit activity against triple-negative breast cancer in vitro and in vivo.
Hsieh MT; Chang LC; Hung HY; Lin HY; Shih MH; Tsai CH; Kuo SC; Lee KH
Eur J Med Chem; 2017 May; 131():141-151. PubMed ID: 28319780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
